CAPTION: German vaccine developer BioNTech posts 30% turnover hike in H1. (picture alliance / dpa)
German pharmaceutical company BioNTech - which partnered with US giant Pfizer to bring one of the world's first coronavirus vaccines to market - increased its turnover in the first half of the year by 30.1% to €9.57 billion ($9.74 billion) compared to the first half of 2021.
Net profit increased by 37.2% to €5.37 billion, the company announced in Mainz on Monday.
Looking at the second quarter alone, however, there was a decline in both sales (down 39.8% to €3.2 billion) and profits (down 40% to €1.67 billion) compared to the same period last year.
The vaccine manufacturer attributed this to the fact that the development of the pandemic "led to a shift in orders and thus to fluctuations in quarterly sales."
The company reaffirmed its full-year 2022 forecast for COVID-19 vaccine sales of between €13 billion and €17 billion.
BioNTech said a clinical trial of a vaccine adapted to two Omicron subvariants would begin this month. If approved by the relevant authorities, the first doses could be delivered from October.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
